The company operates wind power farms in Maharashtra and, through its subsidiaries, develops and manages large-scale infrastructure projects including toll roads and integrated townships.
While the company holds regulatory licenses for wind power and infrastructure concessions, these are offset by severe litigation and accounting disputes. The high ROE is distorted by extreme leverage and negative equity in certain subsidiaries rather than sustainable pricing power.
Capital is largely tied up in long-term infrastructure projects and legal disputes. Significant funds are locked in interest-free advances to subsidiaries that have remained outstanding for over 14 years without clear recovery timelines.
The investment collapsed as the adverse audit opinion materialized into a full-scale financial restatement, revealing that the high ROE was a mirage built on unsustainable leverage and misclassified liabilities. The SIAC arbitration ruling went against the company, triggering a 5,000 million INR cash outflow that the balance sheet could not support, while the 14-year-old 'interest-free advances' were finally written off as unrecoverable. With the stock relegated to the 'Z' category and promoters suspended for non-compliance, institutional liquidity evaporated, leaving shareholders holding equity in a debt-laden shell of disputed infrastructure assets.
RichFakir rates BF Utilities Ltd's business quality as poor — 40/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, BF Utilities Ltd is trading about 15% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on BF Utilities Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of BF Utilities Ltd's fair value is about ₹506 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →